

Mexico City, November 1, 2021.

**Médica Sur, S.A.B. de C.V. ("Médica Sur" or the "Company")** announces that, pursuant to the previously disclosed information regarding the sale of 100% of the capital stock of its subsidiary Laboratorio Médico Polanco, S.A. de C.V. ("LMP"), in which the Company acted as seller, to SDHM, S.A. de C.V., ("SDHM"), a subsidiary of SYNLAB International GmbH ("Synlab"), as purchaser. The said transaction became effective today. The transaction was approved at a Company shareholders' meeting held On October 19, 2021. The approval of the Federal Competition Commission was notified on October 14, 2021.

Revenues from LMP, during fiscal year 2020, amounted to MXN 1.3 billion, including revenues derived from COVID services.

The transaction is valued at a base price of MXN 2.250 billion, with the addition of a variable portion subject to the fulfillment of conditions agreed by the parties for fiscal years 2021 and 2022.

Proceeds from the LMP transaction will allow Médica Sur to continue strengthening its strategy, aimed at improving its medical infrastructure in the country.

For further details regarding the transaction, reader is advised to consult the Information Statement on Corporate Restructuring (Corporate Restructuring Prospectus), filed by the Company on October 4, 2021. A subsequent update on the transaction is included in the Company's report for the third quarter of the current year.

Médica Sur is committed to continue offering the highest quality medicine focused on its patients. To this end, it has the best medical team and collaborators, which has allowed it to be recognized as the "Best Hospital in Mexico", as well as to obtain the distinction of "Exceptional Company", for its adaptive response strategies in the face of the pandemic.

#### About Médica Sur

Médica Sur, S.A.B. de C.V. (BMV ticker symbols: MEDICAB and MEDICA 20) is a hospital operator and an integrated provider of healthcare and related services, provided through hospitals and laboratories. MEDICA relies on a group of physicians, medical professionals, nurses, administration and hospital operations aimed at offering a medical service of excellence with a human approach guided by a strict code of ethics and supported by medical equipment and infrastructure with state-of-the-art technology.

#### Forward-Looking Statements

This report contains forward-looking statements. Such statements include, but are not limited to: (i) statements regarding our financial condition and operating results; (ii) statements regarding our plans, objectives, or targets, including statements with respect to our activities; and (iii) statements regarding the underlying assumptions on which those statements are based. Forward-looking statements contain words such as "intends," "anticipates," "considers," "estimates," "expects," "foresees," "plans," "predicts," "seeks," "could," "should," "possible," "guideline," and other similar terms, whether in first or third person. However, these are not the only terms used to identify these statements. By their very nature, forward-looking statements involve risks and uncertainties of both a general and a specific nature, including the risk that such predictions, forecasts, projection and other forward-looking statement will not be fulfilled. Investors are cautioned that there are many important factors that may cause actual results to differ materially from those expressed in the plans, objectives, expectations, estimates and statements, both expressed and implied, contained in the forwards-looking statements. The information related to future performance contained in this press release must be read jointly with the risks included in the "Risk Factors" section submitted to the National Banking and Securities Commission (CNBV).



#### CONTACT

Investor Relations: Arely Gutiérrez

Ph: 52(55) 5424 7200 Ext. 3425: [agutierrezg@medicasur.org.mx](mailto:agutierrezg@medicasur.org.mx)